CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rubius Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rubius Therapeutics Inc
C/O VERDOLINO & LOWEY
P.C., 124 WASHINGTON STREET, SUITE 101
Phone: (617) 679-9600p:617 679-9600 FOXBORO, MA  02035  United States Fax: (302) 655-5049f:302 655-5049
This company ceased filing statements with the SEC on 4/10/2023.
This company is no longer actively traded on any major stock exchange.
Business Summary
Rubius Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing a platform and pipeline that is focused on creating cellular medicines called Red Cell Therapeutics. The Company’s Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create selective and allogeneic cellular medicines for treating a range of diseases. Red Cell Therapeutics can also be used to kill tumors in cancer, regulate the immune system for the treatment of autoimmune diseases and treat a number of other types of illnesses. The Company’s subsidiary is Rubius Therapeutics Securities Corporation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer & Director Pablo J.Cagnoni
President, Treasurer, Corporate Secretary, Director Craig R.Jalbert 61 3/4/2023 3/4/2023
Chief Financial Officer Andrew M.Oh
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Rubius Therapeutics Securities Corporation
RUBY

General Information
Number of Employees: 6 (As of 1/31/2023)
Outstanding Shares: 90,482,951 (As of 3/6/2023)
Shareholders: 13
Stock Exchange: OTC
Federal Tax Id: 042688109
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 1, 2024